Company intelligence / Profile preview

Jiangsu AnPac Health Management

Lishui, Zhejiang, China

Ownership: Private
Development stage: Other

Overview

AnPac Bio-Medical Science commercializes laboratory-developed multi-cancer early detection tests based on its proprietary cancer differentiation analysis (CDA) technology, with over 300,000 test samples run and revenues generated from cancer screening services in China since 2015, but no therapeutic products and no FDA-approved IVD device yet.[2][8][17]

Therapeutic areas: Oncology
Modalities: Diagnostic testDeviceNon-pharmacological therapy
Industry: Protein Biomarker Diagnostics

Beyond the preview

Go deeper on Jiangsu AnPac Health Management.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jiangsu AnPac Health Management.

Explore the full profile